Arterial patency after repeated hepatic artery bland particle embolization
- PMID: 20188589
- PMCID: PMC6615059
- DOI: 10.1016/j.jvir.2009.12.390
Arterial patency after repeated hepatic artery bland particle embolization
Abstract
Purpose: To evaluate hepatic arterial patency after serial bland particle embolization procedures in patients with hepatocellular carcinoma (HCC).
Materials and methods: All patients with HCC who underwent five or more hepatic artery bland embolization procedures with permanent particulate and spherical embolic agents between September 1996 and December 2007 were retrospectively reviewed. Data analyzed included patient demographics, vessels embolized, embolic agent used, and duration of arterial patency.
Results: Forty-three patients were identified who underwent five or more bland embolization procedures in the same arterial distribution. Of the 43 patients examined, 83% (n = 36) showed no change in the hepatic arterial tree after repeated bland embolization (mean treatment period of 48 months +/- 23). Six patients (13%) exhibited occlusion of a fifth-order or more distal vessel after an average of 5 embolizations +/- 2 over a period of 34 months +/- 27. A single case of vascular occlusion of a fourth-order vessel was observed after five embolizations over a period of 52 months.
Conclusions: Repeated bland embolization of the hepatic arteries in HCC preserves patency of the hepatic arterial vasculature despite the fact that embolization is carried out to complete stasis.
Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
None of the authors have identified a conflict of interest.
Figures


Similar articles
-
Safety and feasibility of outpatient transcatheter hepatic arterial embolization for hepatocellular carcinoma.J Vasc Interv Radiol. 2009 Feb;20(2):203-8. doi: 10.1016/j.jvir.2008.10.027. Epub 2008 Dec 20. J Vasc Interv Radiol. 2009. PMID: 19097805 Clinical Trial.
-
Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response.Cardiovasc Intervent Radiol. 2018 Jan;41(1):104-111. doi: 10.1007/s00270-017-1758-2. Epub 2017 Aug 2. Cardiovasc Intervent Radiol. 2018. PMID: 28770316 Free PMC article.
-
Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma.J Vasc Interv Radiol. 2008 Jun;19(6):862-9. doi: 10.1016/j.jvir.2008.02.013. Epub 2008 Apr 10. J Vasc Interv Radiol. 2008. PMID: 18503900
-
Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments.Minim Invasive Ther Allied Technol. 2018 Apr;27(2):69-80. doi: 10.1080/13645706.2018.1432489. Epub 2018 Jan 30. Minim Invasive Ther Allied Technol. 2018. PMID: 29381102 Review.
-
Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.AJR Am J Roentgenol. 2010 Jul;195(1):245-51. doi: 10.2214/AJR.08.2301. AJR Am J Roentgenol. 2010. PMID: 20566824 Review.
Cited by
-
Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.Radiol Med. 2020 Jan;125(1):98-106. doi: 10.1007/s11547-019-01093-x. Epub 2019 Oct 3. Radiol Med. 2020. PMID: 31583558
-
Oncopharmacology in Interventional Radiology.Semin Intervent Radiol. 2022 Nov 17;39(4):411-415. doi: 10.1055/s-0042-1758076. eCollection 2022 Aug. Semin Intervent Radiol. 2022. PMID: 36406031 Free PMC article. Review.
-
Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.World J Gastroenterol. 2016 Mar 21;22(11):3127-49. doi: 10.3748/wjg.v22.i11.3127. World J Gastroenterol. 2016. PMID: 27003990 Free PMC article. Review.
-
Intermediate hepatocellular carcinoma: the role of transarterial therapy.Hepat Oncol. 2015 Oct;2(4):399-408. doi: 10.2217/hep.15.32. Hepat Oncol. 2015. PMID: 26998220 Free PMC article.
-
Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Cancer Control. 2017 Jul-Sep;24(3):1073274817729244. doi: 10.1177/1073274817729244. Cancer Control. 2017. PMID: 28975829 Free PMC article. Review.
References
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74–108. - PubMed
-
- Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcino-genesis and prevention. Cancer Epidemiol Biomarkers Prev 1993; 2:537–544. - PubMed
-
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907–1917. - PubMed
-
- Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6–25. - PubMed
-
- Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003; 26:111–117. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical